Mirum Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
MIRM$94.42+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(64,152) | $(127,756) |
| Reconciliation of net loss to net cash provided by (used in) operating activities: | ||
| Stock-based compensation | 35,193 | 25,303 |
| Depreciation and amortization | 17,573 | 5,335 |
| Inventory reserves and firm commitment losses | 1,783 | 1,491 |
| Amortization of debt discount and offering costs | 1,245 | 718 |
| Loss from termination of revenue interest purchase agreement | — | 49,076 |
| Non-cash interest expense related to the revenue interest liability | — | 5,060 |
| Unrealized foreign exchange gain | (1,082) | (1,230) |
| Non-cash lease expense | 985 | 476 |
| Other | (425) | (1,025) |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (562) | (23,840) |
| Prepaid and other current assets | (1,122) | (3,447) |
| Inventory | (2,952) | (2,206) |
| Other assets | (1,496) | 180 |
| Accounts payable, accrued expenses and other liabilities | 30,973 | 18,250 |
| Operating lease liabilities | (568) | (711) |
| Net cash provided by (used in) operating activities | 15,393 | (54,326) |
| Investing activities | ||
| Purchase of investments | (77,543) | (27,329) |
| Proceeds from maturities of investments | 7,750 | 150,000 |
| Purchase of property and equipment | (973) | (109) |
| Cash paid for acquisition | — | (212,762) |
| Payments made for additions to intangible assets | (20,000) | (15,000) |
| Net cash used in investing activities | (90,766) | (105,200) |
| Financing activities | ||
| Proceeds from issuance of common stock in private placement, net of issuance costs | — | 202,363 |
| Proceeds from issuance of common stock in at-the-market offerings, net of issuance costs | — | 14,480 |
| Proceeds from issuance of convertible notes, net | — | 305,304 |
| Proceeds from issuance of common stock pursuant to equity plans | 12,359 | 8,253 |
| Payments on revenue interest liability | — | (195,577) |
| Net cash provided by financing activities | 12,359 | 334,823 |
| Effect of exchange rate on cash, cash equivalents and restricted cash equivalents | 82 | (241) |
| Net (decrease) increase in cash, cash equivalents and restricted cash equivalents | (62,932) | 175,056 |
| Cash, cash equivalents and restricted cash equivalents at beginning of period | 286,326 | 128,003 |
| Cash, cash equivalents and restricted cash at end of period | $223,394 | $303,059 |
| Supplemental disclosure of cash flow information: | ||
| Operating cash flows paid for operating lease | $881 | $824 |
| Cash paid for interest | $6,325 | $— |
| Cash paid for income taxes | $771 | $— |
| Non-cash operating, investing and financing activities: | ||
| Accrued milestone payments classified as intangible assets, net | $— | $5,000 |
| Right-of-use assets obtained in exchange for lease liabilities | $9,633 | $473 |
| Decrease in ROU assets and lease liabilities due to lease modification | $723 | $— |
| Stock-based compensation capitalized to inventory | $909 | $578 |
| Issuance of common stock in connection with settlement of Contingent Milestone and Indemnification Holdback liabilities | $— | $5,188 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.